Trial Profile
A phase II study of OGX-011 given prior to radical prostatectomy in patients with localized prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Custirsen (Primary) ; Antiandrogens
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Mar 2017 Status changed from active, no longer recruiting to completed.
- 04 Oct 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 24 Sep 2010 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.